Company Overview and News
Shares of Kirloskar Ferrous Industries and Uttam Galva Steel rose 3.5 percent and 12 percent respectively intraday Tuesday on strong Q4 (January-March) numbers.
For the full year,net profit rose 56.89% to Rs 90.57 crore in the year ended March 2017 as against Rs 57.73 crore during the previous year ended March 2016. Sales rose 1.91% to Rs 1127.10 crore in the year ended March 2017 as against Rs 1105.93 crore during the previous year ended March 2016.
Kirloskar Ferrous Industries said the upgradation of a mini blast furnace at the company’s plant in Koppal, Karnataka, has been completed and commercial production resumed from Tuesday. The unit was shut on September 19 to upgrade the blast furnace, Kirloskar Ferrous said in an exchange filing. Shares of Kirloskar Ferrous were up about a per cent at ₹76.70 on the BSE.
The Indian markets on Tuesday closed in the red, with Sensex closing 52.51 points down from its previous close.
In order to serve content on our website, we rely on advertising revenue which helps us to ensure that we continue to serve high quality, unbiased journalism.
ICICI Bank | Ultratech Cement | Reliance Infrastructure | SAIL | Eicher Motors | Muthoot Finance | L&T Infotech | Ador Welding | Kirloskar Ferrous | Gujarat Alkalies | Deep Industries | GSFC | TNPL | KCP Sugar | Ortel Communications and De Nora India are stocks, which are in the news today.
Meghmani Organics on Thursday informed the exchanges of a fire mishap at its Dahej SEZ plant, Dahej, Gujarat. The fire broke out at 22.25 IST on Wednesday in one of the manufacturing sections of its pigment manufacturing division. The plant has four manufacturing sections supported by other sub-sections. Only one manufacturing section of Beta Blue got affected due to the fire. All staff members are safe and no one was injured during the incident.
Kirloskar Ferrous Industries today said it will acquire VSL Steels's pig iron plant for Rs 155 crore in cash. "Board at its meeting on July 28, has granted in-principle approval for acquisition of movable and immovable assets relating to pig iron plant of VSL Steels Ltd for a cash consideration of Rs 155 crore," Kirloskar Ferrous Industries said in a regulatory filing. The amount will be payable in installments and will be subject to certain commercial conditions, necessary governmental or regulatory approvals and the approval of the Board and shareholders of VSL Steels Ltd, it added.
Kirloskar Ferrous Industries today said it will acquire VSL Steels’ pig iron plant for Rs 155 crore.
"Board at its meeting on July 28, has granted in-principle approval for acquisition of movable and immovable assets relating to pig iron plant of VSL Steels Ltd for a cash consideration of Rs 155 crore," Kirloskar Ferrous Industries said in a regulatory filing.
3m - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...